Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Eden vs Garcia Weight Loss, Aesthetics & Hormone Therapy

Two GLP-1 desks, one scoreboard. We put Eden and Garcia Weight Loss, Aesthetics & Hormone Therapy head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 3 · Grade A−

Eden

Visit Eden Full brief →
vs
No. 306 · Grade C

Garcia Weight Loss, Aesthetics & Hormone Therapy

Visit Garcia Weight Loss, Aesthetics & Hormone Therapy Full brief →

The verdict

Eden takes this head-to-head.

Eden scores 91 to 61 on our six-factor Brief Score — A polished, high-disclosure program with strong nationwide coverage — you pay more, but you know exactly what you're paying for.

That doesn't make Garcia Weight Loss, Aesthetics & Hormone Therapy a bad call — it's best for readers who want florida residents who want an established in-person weight-loss clinic with provider-supervised glp-1 care. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
89
48
Supply Reliability
92
73
Transparency
93
48
Access Breadth
90
46
Clinical Oversight
92
79
Track Record
89
84
EdenBrief Score 91 · 61Garcia Weight Loss, Aesthetics & Hormone Therapy

Price, coverage & the tracker

EdenGarcia Weight Loss, Aesthetics & Hormone Therapy
Brief Score91/100 (A−)61/100 (C)
Semaglutide$239/moFrom $400/mo (starting dose, compounded)
Tirzepatide$349/moNot disclosed
CoverageAll 50 states1 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

Eden: Premium line steady; high supply-chain disclosure keeps our confidence high.

Garcia Weight Loss, Aesthetics & Hormone Therapy: New to the tracker on 1 August 2026. The published line reads From $400/mo (starting dose, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.